Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Xu‐Dong Qu"'
Autor:
Jia-Cheng Lu, Lei-Lei Wu, Yi-Ning Sun, Xiao-Yong Huang, Chao Gao, Xiao-Jun Guo, Hai-Ying Zeng, Xu-Dong Qu, Yi Chen, Dong Wu, Yan-Zi Pei, Xian-Long Meng, Yi-Min Zheng, Chen Liang, Peng-Fei Zhang, Jia-Bin Cai, Zhen-Bin Ding, Guo-Huan Yang, Ning Ren, Cheng Huang, Xiao-Ying Wang, Qiang Gao, Qi-Man Sun, Ying-Hong Shi, Shuang-Jian Qiu, Ai-Wu Ke, Guo-Ming Shi, Jian Zhou, Yi-Di Sun, Jia Fan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-23 (2024)
Abstract Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR
Externí odkaz:
https://doaj.org/article/1395aad7bace40e0b84d6d1fe593d121
Autor:
Zi-Han Zhang, Si-Nan Hou, Jia-Ze Yu, Wen Zhang, Jing-Qin Ma, Min-Jie Yang, Qing-Xin Liu, Ling-Xiao Liu, Jian-Jun Luo, Xu-Dong Qu, Zhi-Ping Yan
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
ObjectiveTo evaluate the safety and efficacy of interventional therapy (iodine-125[125I] seed strand and portal vein stent [PVS] implantation plus transarterial chemoembolization [TACE]) combined with systemic therapy (lenvatinib plus anti-PD-1 antib
Externí odkaz:
https://doaj.org/article/a667eabe92c742d39ebda9aa9c267ec4
Autor:
Xiao-Dong Zhu, Cheng Huang, Ying-Hao Shen, Yuan Ji, Ning-Ling Ge, Xu-Dong Qu, Lingli Chen, Wen-Kai Shi, Mei-Ling Li, Jin-Jin Zhu, Chang-Jun Tan, Zhao-You Tang, Jian Zhou, Jia Fan, Hui-Chuan Sun
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Background: Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies has shown high tumor response rates for patients with unresectable hepatocellular carcinoma (HCC). However, using this treatment strategy to convert initiall
Externí odkaz:
https://doaj.org/article/c215b3559eae461aa196e42bf6ed209f
Publikováno v:
Water Science and Engineering, Vol 12, Iss 3, Pp 205-212 (2019)
Extracting implicit anomaly information through deformation monitoring data mining is highly significant to determining dam safety status. As an intelligent singular value diagnostic method for concrete dam deformation monitoring, shallow neural netw
Externí odkaz:
https://doaj.org/article/e0cb6b2670c345c19f73eac7653c2669
Autor:
Peng‐Xiang Wang, Yun‐Fan Sun, Kai‐Qian Zhou, Jian‐Wen Cheng, Bo Hu, Wei Guo, Yue Yin, Jun‐Feng Huang, Jian Zhou, Jia Fan, Tan To Cheung, Xu‐Dong Qu, Xin‐Rong Yang
Publikováno v:
Clinical and Translational Medicine, Vol 10, Iss 3, Pp n/a-n/a (2020)
Abstract Background High rates of postoperative tumor recurrence contribute to poor outcome in hepatocellular carcinoma (HCC). Here, we investigated whether circulating tumor cells (CTCs) status can predict the benefit of adjuvant transcatheter arter
Externí odkaz:
https://doaj.org/article/ea98e2d6a7cc4046ac69f230f3c93715
Autor:
Xiao-Dong Zhu, Cheng Huang, Ying-Hao Shen, Bin Xu, Ning-Ling Ge, Yuan Ji, Xu-Dong Qu, Lingli Chen, Yi Chen, Mei-Ling Li, Jin-Jin Zhu, Zhao-You Tang, Jian Zhou, Jia Fan, Hui-Chuan Sun
Publikováno v:
Annals of Surgical Oncology. 30:2791-2792
Autor:
Wei-Feng Qu, Zhen-Bin Ding, Xu-Dong Qu, Zheng Tang, Gui-Qi Zhu, Xiu-Tao Fu, Zi-Han Zhang, Xin Zhang, Ao Huang, Min Tang, Meng-Xin Tian, Xi-Fei Jiang, Run Huang, Chen-Yang Tao, Yuan Fang, Jun Gao, Xiao-Ling Wu, Jian Zhou, Jia Fan, Wei-Ren Liu, Ying-Hong Shi
Publikováno v:
BJS Open. 6
Background Combination conversion therapies afforded curative surgery chance for initially unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the conversion rate and clinical outcomes of a first-line conversion regimen of lenv
Autor:
Zi-Han Zhang, Si-Nan Hou, Jia-Ze Yu, Xin Zhou, Wen Zhang, Jing-Qin Ma, Min-Jie Yang, Qing-Xin Liu, Ling-Xiao Liu, Jian-Jun Luo, Xu-Dong Qu, Zhi-Ping Yan
Purpose To evaluate the safety and efficacy of interventional therapy (iodine-125 seed strand [with or without stent] implantation plus transarterial chemoembolization) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) as first-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::958c576f560e17f89388a7b8c7c77b14
https://doi.org/10.21203/rs.3.rs-1872653/v1
https://doi.org/10.21203/rs.3.rs-1872653/v1
Autor:
Xiao-Dong Zhu, Cheng Huang, Ying-Hao Shen, Bin Xu, Ning-Ling Ge, Yuan Ji, Xu-Dong Qu, Lingli Chen, Yi Chen, Mei-Ling Li, Jin-Jin Zhu, Zhao-You Tang, Jian Zhou, Jia Fan, Hui-Chuan Sun
Publikováno v:
Annals of surgical oncology.
Background Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term sur
Autor:
Ning-Ling Ge, Lingli Chen, Mei-Ling Li, Chang-Jun Tan, Xiao-Dong Zhu, Xu-Dong Qu, Jian Zhou, Zhao-You Tang, Yuan Ji, Jia Fan, J. Zhu, Wen-Kai Shi, Ying-Hao Shen, Cheng Huang, Hui-Chuan Sun
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Liver Cancer
Liver Cancer
Background: Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies has shown high tumor response rates for patients with unresectable hepatocellular carcinoma (HCC). However, using this treatment strategy to convert initiall